Nbm-Bmx
Eye Cancer, Intraocular Melanoma
Novelwise Pharmaceutical CorporationPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Eye Cancer, Intraocular Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MELATONIN Gustav Stalhammar | Phase 3 | B |
Same molecule, other indications
Nbm-Bmx is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →